Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.10 |
---|---|
High | 8.10 |
Low | 8.10 |
Bid | 8.10 |
Offer | 8.50 |
Previous close | 8.20 |
Average volume | 222.22 |
---|---|
Shares outstanding | 865.86m |
Free float | 636.64m |
P/E (TTM) | -- |
Market cap | 62.51bn HKD |
EPS (TTM) | -0.9619 HKD |
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Press releases
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
- Summit Therapeutics Raises $235 Million
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
- HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
- Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
- Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
- Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
- Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
More ▼